WHO Pharmaceuticals Newsletter 2003, No. 03
(2003; 14 pages) Ver el documento en el formato PDF
Índice de contenido
Cerrar esta carpetaREGULATORY MATTERS
Ver el documentoACETYLSALICYLIC ACID - MHRA confirms labelling change
Ver el documentoACITRETIN - Warnings of depression added to label
Ver el documentoASTEMIZOLE - Withdrawn due to life-threatening ventricular arrhythmias
Ver el documentoCAMELIA SINENSIS - Ethanolic extract products withdrawn due to hepatotoxicity
Ver el documentoDIETARY SUPPLEMENTS - Withdrawal of two products due to presence of sildenafil
Ver el documentoHUA FO - Presence of tadalafil
Ver el documentoIODINE - Some products contain more than the RDA
Ver el documentoLEVODOPA/CARBIDOPA - New warning about somnolence and sudden onset sleep
Ver el documentoLINDANE - Additional warnings and medication guide added to label
Ver el documentoNEFAZODONE - Regulatory status update
Ver el documentoNIMESULIDE - Paediatric preparations banned in Bangladesh
Ver el documentoPERGOLIDE MESYLATE - Risk of cardiac valvulopathy
Ver el documentoREPAGLINIDE - Contraindicated with gemfibrozil
Ver el documentoRISPERIDONE - Prescribing information updated to reflect cardiovascular adverse events
Ver el documentoTELITHROMYCIN - Aggravation of myasthenia gravis
Abrir esta carpeta y ver su contenidoSAFETY OF MEDICINES
Abrir esta carpeta y ver su contenidoCURRENT CONCERNS
Abrir esta carpeta y ver su contenidoDRUGS OF INTEREST
Abrir esta carpeta y ver su contenidoFEATURE

NEFAZODONE - Regulatory status update

Republic of Turkey1. The Directorate General of Pharmaceuticals and Pharmacy has decided to suspend the license for nefazodone hydrochloride preparations (Serzone) held by Bristol Myers Squibb Drugs Inc in Turkey. This decision has been taken in view of the latest data received by the Turkish Ministry of Health as well as worldwide developments that suggest acute hepatic failure associated with nefazodone use. A variety of other antidepressant agents are available in the market and can be used effectively in its place. Procedures to stop further prescription and withdrawal of nefazodone (Serzone) from the market have been initiated.

Singapore2. Since nefazodone, indicated for the treatment of depression, was licensed in Singapore in 1997, the Pharmacovigilance Unit has received one local adverse drug reaction (ADR) report of mildly elevated ALT levels associated with nefazodone. Up to December 2002, 28 reports of liver failure, including 15 which resulted in death, associated with nefazodone had been received worldwide. In Singapore the package insert for nefazodone (Serzone) has been amended to include warnings relating to the risk of hepatic adverse events and a ‘Dear Healthcare Professional’ letter was issued in February 2002 to inform physicians of these amendments.

Reports in WHO-file: Liver and biliary system disorders 474


1. Communication from the Division of Pharmacovigilance, Ministry of Health, Republic of Turkey, 21 March 2003

2. Adverse Drug Reaction News (Singapore), 5:1, Feb 2003.

Ir a la sección anterior
Ir a la siguiente sección
El Portal de Información - Medicamentos Esenciales y Productos de Salud de la OMS fue diseñado y es mantenido por la ONG Human Info. Última actualización: le 1 diciembre 2019